A trial looking at different ways of having isatuximab for multiple myeloma that has come back or stopped responding to treatment (IRAKLIA)

This trial is looking at having isatuximab as a drip into your bloodstream (intravenous) or as an injection under your skin (subcutaneous).

It is for people with multiple myeloma that:

• has come back after the initial treatment (relapsed multiple myeloma)

• continued to grow despite treatment (refractory multiple myeloma)